Related Experiment Video
Updated: May 28, 2026
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Timing of ganciclovir administration in glioma gene therapy using HSVtk gene-transduced mesenchymal stem cells
Shinji Amano1, Chunyu Gu, Shinichiro Koizumi
1Department of Neurosurgery, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan.
Background:
An established C6 glioma was successfully treated with intratumoral injection of mesenchymal stem cells transduced with HSVtk gene (MSCtk) and systemic administration of ganciclovir (GCV). The best timing of GCV administration after the MSCtk implantation was studied.
Materials And Methods:
GCV administration was started from 2 days before and 1, 3 and 7 days after the MSCtk administration under both in vitro and in vivo conditions.
Results:
The C6 cells were completely eradicated in vitro when GCV administration was started from day -2, 1, and 3. Animals with intracranial tumor survived longer when GCV was administered earlier after MSCtk administration. This may, mainly, reflect the difference in the MSCtk/C6 ratio at the time of GCV administration because this ratio drastically decreases during the delay of GCV administration.
Conclusion:
When using a slowly growing vector cell as MSCtk, GCV should be administered soon after MSCtk implantation.
